Stock analysts at Robert W. Baird initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a report issued on Monday. The firm set an “outperform” rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the company. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Monday, October 16th. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday, February 6th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $5.00 target price on shares of Genocea Biosciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Genocea Biosciences has an average rating of “Hold” and an average target price of $4.45.
Shares of Genocea Biosciences (NASDAQ GNCA) opened at $0.93 on Monday. The stock has a market capitalization of $76.32, a PE ratio of -0.43 and a beta of 1.56. Genocea Biosciences has a twelve month low of $0.79 and a twelve month high of $7.29. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 2.51.
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Genocea Biosciences by 13.9% during the 2nd quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after purchasing an additional 104,790 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Genocea Biosciences by 642.9% during the 2nd quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock worth $1,601,000 after purchasing an additional 265,328 shares during the last quarter. OxFORD Asset Management LLP acquired a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $204,000. GSA Capital Partners LLP acquired a new position in shares of Genocea Biosciences during the 2nd quarter worth approximately $100,000. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 2,300 shares during the last quarter. Institutional investors and hedge funds own 12.03% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Robert W. Baird Begins Coverage on Genocea Biosciences (GNCA)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/12/robert-w-baird-begins-coverage-on-genocea-biosciences-gnca.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.